Clinical Trial Search

Primary: Progression-Free Survival, as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) — 12.4; 14.5; 12.5; 16.5 months…

Primary: Change in the Total Atheroma Volume From Baseline to 12 Weeks — -7.63; -3.10 mm^3 — p=0.2533

Primary: Number of Participants With Adverse Events (AEs) — 136 Participants

Primary: Total Combined Score (TCS) During the Peak Ragweed Season (RS) — 4.39; 7.12 Score on a scale — p=< 0.001

Primary: Number of Women With Clinical Cure at the End of Treatment Visit (EOT) — 68; 25 Participants — p=<0.001

Primary: Time to AVF Primary Unassisted Patency — 214; 171 Days — p=0.254

Primary: Number of Participants in Clinical Remission on Canakinumab Who Are Able to Remain at an Initial Reduced Canakinumab Dose or Prolonged Canakinumab Dose Interval. — 27…

Primary: Time to Delivery — 28.1; 20.1 hours — p=0.663

Primary: Recurrence of BV Where a Diagnosis of BV is Defined as the Presence of at Least 3 Clinical Findings — 130; 158 Participants — p=0.015

Primary: Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 12 — 366; 265 Participants — p=<0.0001

Primary: Number of Women With Clinical Cure at the End of Treatment Visit (EOT) — 59; 19 Participants — p=<0.001

Primary: Change in Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) Combined Scores, Baseline to 30 Minutes Post Dose — -6.1; 2.5 number of questions answered correctly…

Primary: SVR12 (Reinfection Not Considered Failure) — 79 participants

Primary: Mean Change in Daily OFF Time From Baseline (Start of Blinded Treatment) to the End of Double-blind Phase (Visit 10) Based on Patient Diaries Using MMRM mITT Population…

Primary: Mean Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) Z-score at Month 12 — 0.582; 0.168 Z-score — p=0.0392